| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-07-29 | Impax Laboratories (USA - CA) | Rytary™ (extended-release capsule formulation of carbidopa and levodopa) | Parkinson\'s disease | inspection of a production plant |
Neurodegenerative diseases | Validation of a production plant |
| 2014-07-29 | ARTES Biotechnology (Germany) Burnet Institute (Australia) PATH Malaria Vaccine Initiative (MVI) | malaria vaccine | malaria | development |
Infectious diseases - Parasitic diseases | Development agreement |
| 2014-07-29 | Roche (Switzerland) Amorchem (Canada) NuChem Therapeutics (Canada) | novel small molecule disease-modifying therapy | myotonic muscular dystrophy 1or Steinert’s disease | R&D collaboration |
Rare diseases - Neuromuscular diseases - Genetic diseases | R&D agreement |
| 2014-07-28 | AstraZeneca (UK) Qiagen (The Netherlands) | liquid biopsy-based companion diagnostic to be paired with Iressa® | non-small cell lung cancer | development |
Cancer - Oncology | Development agreement |
| 2014-07-28 | KaloBios Pharmaceuticals (USA -CA) Sanofi Pasteur (France) | KB001A | Pseudomonas aeruginosa pneumonia | collaboration licensing |
Infectious diseases - Respiratory diseases - Lung diseases | Termination of an agreement |
| 2014-07-28 | Valneva (France - Austria) undisclosed global animal health company | antibodies from animal B-lymphocytes using Valneva’s proprietary VIVA|Screen® technology | Veterinary medicine | Licensing agreement | ||
| 2014-07-28 | AstraZeneca (UK) Roche (Switzerland) | plasma-based companion diagnostic test for AZD9291 | non-small-cell lung cancer (NSCLC) | development |
Cancer - Oncology | Development agreement |
| 2014-07-28 | CANbridge Life Sciences (China) EUSA Pharma, a division of Jazz Pharmaceuticals (Ireland) | Caphosol® | oral mucositis | Cancer - Oncology | Commercialisation agreement | |
| 2014-07-25 | Horizon Discovery (UK) Otsuka Pharmaceutical Development and Commercialization (Japan) | in-vitro cell line screening | services |
Technology - Services | Services contract | |
| 2014-07-24 | GENALICE (The Netherlands) deCODE Genetics an Amgen\'s subsidiary (Iceland) | GENALICE MAP | collaboration |
Technology - Services | Collaboration agreement | |
| 2014-07-24 | Roche (Switzerland) Advanced Biological Laboratories (Luxembourg) | Next-Generation Sequencing, Genotyping and Drug Resistance Products | hepatitis B, hepatitis C, HIV | collaboration |
Diagnostic - Infectious diseases | Collaboration agreement |
| 2014-07-24 | Gilead (USA - CA) Medicines Patent Pool | tenofovir alafenamide | hepatitis B, HIV | licensing |
Infectious diseases | Licensing agreement |
| 2014-07-24 | Merck Serono (Germany) Institute of Experimental Neurology (INSPE) of San Raffaele University and Research Hospital (Italy) | neurological diseases such as multiple sclerosis | collaboration development |
Neurodegenerative diseases | Development agreement | |
| 2014-07-24 | Protalix BioTherapeutics (Israel) | chairman of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2014-07-24 | Qiagen (The Netherlands) University of Tokyo (Japan) | biomarker SF3B1 | myelodysplastic syndromes | licensing |
Diagnostic - Cancer - Oncology | Licensing agreement |
| 2014-07-23 | Merck KGaA, Merck Serono (Germany) | construction of a production plant |
Cancer - Oncology - Women's health - Cardiovascular diseases - Metabolic diseases | Construction of a production plant | ||
| 2014-07-23 | BMS (USA - NY) Ono Pharmaceutical (Japan) | Opdivo® (nivolumab), Yervoy® (ipilimumab), lirilumab, urelumab and BMS-986016 as single agents and combination regimens | various tumor types | development |
Cancer - Oncology | Development agreement |
| 2014-07-23 | Juventas Therapeutics (USA - OH) | chief financial officer, chief strategy officer | nomination | Cardiovascular diseases | Nomination | |
| 2014-07-22 | THERAMetrics (Switzerland) Intelligent Pharma (Spain) | company acquisition |
Company acquisition | |||
| 2014-07-22 | MedImmune (USA), the global biologics arm of AstraZeneca (UK), Advaxis (USA - NJ) | MEDI4736 (durvalumab) and ADXS-HPV (axalimogene filolisbac) | advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer, HPV-associated head and neck cancer. | clinical research |
Cancer - Oncology - Infectious diseases | Clinical research agreement |
